87 Results for "

TIE2

" in MedChemExpress (MCE) Product Catalog:
Products (87)

87 Results for "TIE2" in MCE Product Catalog:

  • Isoforms Recommended:
  • Targets Recommended:
  • Recombinant Proteins Recommended:
58
58 Publications Verification
Referencia número: HY-13016
No. CAS: 849217-68-1
Pureza:  99.96%
Synonyms: XL184; BMS-907351
Áreas de investigación:  

Cancer

Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET, with IC50 values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC50=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis [2].
loading...
    loading...
13
13 Cited Publications
Referencia número: HY-13024
No. CAS: 1020172-07-9
Pureza:  99.91%
Synonyms: DCC-2036
Rebastinib (DCC-2036) is an orally active, non-ATP-competitive Bcr-Abl inhibitor, with IC50 values of 0.8 nM and 4 nM against Abl1 WT and Abl1 T315I, respectively. Rebastinib potently inhibits CYP2C8 (IC50 = 0.0533 μM) and CYP2C9 (IC50 = 2.54 μM). Rebastinib allosterically inhibits Tie2 with an IC50 of 0.63 nM. Rebastinib inhibits the transcriptional activity of FoxO1. Rebastinib inhibits SRC family kinases, KDR and FLT3 kinases. Rebastinib induces Apoptosis. Rebastinib exerts anti-tumor activity in breast cancer. Rebastinib exerts anti-angiogenic effects. Rebastinib increases myotube diameter and improves reduced contractility. Rebastinib can be used in research related to triple-negative breast cancer, luminal breast cancer, pancreatic neuroendocrine tumors, muscle atrophy, cancer cachexia, chronic myeloid leukemia, and B-lymphocytic leukemia [2] .
loading...
    loading...
8
8 Cited Publications
Referencia número: HY-12014
No. CAS: 658084-23-2
Pureza:  98.82%
Synonyms: PKI-SU11274
Áreas de investigación:  

Cancer

SU11274 is a selective Met inhibitor with IC50 of 10 nM, but has no effects on PGDFRβ, EGFR or Tie2.
loading...
    loading...
4
4 Cited Publications
Referencia número: HY-109041
No. CAS: 1008510-37-9
Pureza:  ≥98.0%
Synonyms: AKB-9778
Target:  

Phosphatase Tie

Áreas de investigación:  

Inflammation/Immunology

Razuprotafib (AKB-9778) is a potent and selective inhibitor of the catalytic activity of VE-PTP (vascular endothelial protein tyrosine phosphatase) with an IC50of 17 pM. Razuprotafib promotes TIE2 activation, enhances ANG1-induced TIE2 activation, and stimulates phosphorylation of signaling molecules in the TIE2 pathway, including AKT, eNOS, and ERK. Razuprotafib inhibits the structurally related phosphatase PTP1B with an IC50 of 780 nM. Razuprotafib shows excellent selectivity for VE-PTP versus a variety of phosphatases, with the exception of HPTPη (IC50=36 pM) and HPTPγ (100 pM) .
loading...
    loading...
4
4 Cited Publications
Referencia número: HY-108333
No. CAS: 956613-01-7
Pureza:  98.05%
Target:  

Ser/Thr Kinase

Áreas de investigación:  

Cardiovascular Disease Cancer

SB-633825 is a potent and ATP-competitive inhibitor of TIE2, LOK (STK10) and BRK with IC50s of 3.5 nM, 66 nM, 150 nM, respectively. SB-633825 can inhibit cancer cell growth and angiogenesis .
loading...
    loading...
2
2 Cited Publications
Referencia número: HY-16782
No. CAS: 945614-12-0
Synonyms: ARRY-614
Target:  

Tie p38 MAPK Autophagy

Áreas de investigación:  

Cancer

Pexmetinib is a potent Tie-2 and p38 MAPK dual inhibitor, with IC50s of 1 nM, 35 nM and 26 nM for Tie-2, p38α and p38β, respectively, and can be used in the research of acute myeloid leukemia.
loading...
    loading...
1
1 Cited Publications
Referencia número: HY-100556
No. CAS: 948557-43-5
Pureza:  99.80%
Target:  

Tie

Áreas de investigación:  

Cancer

Tie2 kinase inhibitor 1 (compound 5) is a potent, selective Tie2 kinase inhibitor with an IC50 of 250 nM . Tie2 kinase inhibitor 1 has anti-cancer activity [2].
loading...
    loading...
1
1 Cited Publications
Referencia número: HY-16025
No. CAS: 939805-30-8
Synonyms: ACTB-1003
Target:  

FGFR VEGFR

Áreas de investigación:  

Cancer

EOC317 (ACTB-1003) is an oral kinase inhibitor with IC50s of 6, 2 and 4 nM for FGFR1, VEGFR2 and Tie-2.
loading...
    loading...
1
1 Cited Publications
Referencia número: HY-100756
No. CAS: 1448316-08-2
Pureza:  99.28%
Áreas de investigación:  

Cancer

BAY-826, a chemical probe, is a selective and potent TIE-2 inhibitor with a Kd of 1.6 nM, respectively.
loading...
    loading...
1
1 Cited Publications
Referencia número: HY-B0791
No. CAS: 1345847-93-9
Synonyms: DCC-2701
Áreas de investigación:  

Cancer

Altiratinib (DCC-2701) is a multi-targeted kinase inhibitor with IC50s of 2.7, 8, 9.2, 9.3, 0.85, 4.6, 0.83 nM for MET, TIE2, VEGFR2, FLT3, Trk1, Trk2, and Trk3 respectively.
loading...
    loading...
Referencia número: HY-16135
No. CAS: 856691-93-5
Synonyms: ESK981; BOL 303213X
Target:  

VEGFR FGFR

Áreas de investigación:  

Cancer

CEP-11981(ESK981; BOL 303213X) is an orally active tyrosine kinase inhibitor (TKI), which can target TIE2, VEGFR1-3 and FGFR1, and has potential anti-tumor and anti-angiogenic effects .
loading...
    loading...
Referencia número: HY-P99036
No. CAS: 1296818-77-3

Target:  

Tie

Áreas de investigación:  

Cardiovascular Disease Inflammation/Immunology Cancer

Nesvacumab is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that specifically binds and inactivates the Tie2 receptor ligand Angiopoietin-2 (Ang2) with high affinity, but shows no binding to Ang1. Nesvacumab can be used in vascular researches [2].
loading...
    loading...
Referencia número: HY-P99546
No. CAS: 894356-79-7
Synonyms: 2xCon4C; AMG 386

Target:  

Tie

Áreas de investigación:  

Cardiovascular Disease Cancer

Trebananib (2xCon4C) is an Fc fusion peptibody. Trebananib exerts its effects by blocking the binding of angiopoietin 1 (Ang1) and angiopoietin 2 (Ang2) to the TIE2 receptor. Trebananib has anti-angiogenic and anti-tumor activities [2] .
loading...
    loading...
Referencia número: HY-113571
No. CAS: 1020412-97-8
Target:  

Tie

Áreas de investigación:  

Cardiovascular Disease

Tie2 kinase inhibitor 2 (compound 7) is a selective Tie2 kinase inhibitor with an IC50 value of 1 μM. Tie2 kinase inhibitor 2 inhibits endothelial cell tube formation, and can be used for Tie2-mediated angiogenic disorders research .
loading...
    loading...
Referencia número: HY-P10580
No. CAS: 1359657-45-6
Vasculotide is a blood-brain barrier (BBB)-penetrant Tie2 agonist. Vasculotide binds to a unique domain of Tie2, induces receptor clustering to drive phosphorylation, activates downstream PI3K/Akt and eNOS pathways, enhances inter-endothelial cell junctions (such as VE-cadherin and claudin-5), and inhibits inflammatory adhesion molecules, ultimately stabilizing the vascular endothelial barrier and reducing its permeability . Vasculotide alleviates pulmonary microvascular leakage and microcirculatory dysfunction caused by cardiopulmonary bypass, acts as an adjuvant radioprotective agent to reduce acute radiation dermatitis, and promotes BBB recovery after focused ultrasound (FUS). Combination of Vasculotide with antibiotics reduces lung injury [2] .
loading...
    loading...
Referencia número: HY-P3369
No. CAS: 2417491-82-6
Synonyms: AXT-107
Target:  

VEGFR Tie Akt

Gersizangitide (AXT107) is an anti-angiogenic peptide consisting of 20 amino acids, derived from collagen IV. Gersizangitide is an inhibitor of VEGF-A and VEGF-C and an activator of Tie2. Gersizangitide can block VEGF receptor signaling, inhibit vascular leakage, neovascularization and inflammation. Gersizangitide can be used in the research of diseases related to ocular neovascularization and angiogenesis [2].
loading...
    loading...
Referencia número: HY-P5438
Áreas de investigación:  

Others

Srctide is a biological active peptide. (This is a peptide substrate for many protein kinases, such as Blk, BTK, cKit, EPHA1, EPHB2, EPHB3, ERBB4, FAK, Flt3, IGF-1R, ITK, Lck, MET, MUSK, Ret, Src, TIE2, TrkB, VEGF-R1 (Flt-1) and VEGF-R2 (KDR).)
loading...
    loading...
Referencia número: HY-123450
No. CAS: 1257628-57-1
Pureza:  99.60%
Target:  

Bcr-Abl Apoptosis PDGFR

Áreas de investigación:  

Cancer

S116836, a potent, orally active BCR-ABL tyrosine kinase inhibitor, blocks both wild-type as well as T315I Bcr-Abl. S116836 arrests the cells in the G0/G1 phase of cell cycle, induces apoptosis, increases ROS production, and decreases GSH production in BaF3/WT and BaF3/T315I cells. S116836 also inhibits SRC, LYN, HCK, LCK and BLK, and receptor tyrosine kinases such as FLT3, TIE2, KIT, PDGFR-β. Antitumor activies [2] . S116836 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
Referencia número: HY-N2666
No. CAS: 132185-83-2
5α-Hydroxycostic acid, a eudesmane-type sesquiterpene, is isolated from the herb Laggera alata. 5α-Hydroxycostic acid inhibits angiogenesis and suppresses breast cancer cell migration through regulating VEGF/VEGFR2 and Ang2/Tie2 pathways .
loading...
    loading...
Referencia número: HY-P10580A
Vasculotide TFA is a blood-brain barrier (BBB)-penetrant Tie2 agonist. Vasculotide TFA binds to a unique domain of Tie2, induces receptor clustering to drive phosphorylation, activates downstream PI3K/Akt and eNOS pathways, enhances inter-endothelial cell junctions (such as VE-cadherin and claudin-5), and inhibits inflammatory adhesion molecules, ultimately stabilizing the vascular endothelial barrier and reducing its permeability . Vasculotide TFA alleviates pulmonary microvascular leakage and microcirculatory dysfunction caused by cardiopulmonary bypass, acts as an adjuvant radioprotective agent to reduce acute radiation dermatitis, and promotes BBB recovery after focused ultrasound (FUS). Combination of Vasculotide TFA with antibiotics reduces lung injury [2] .
loading...
    loading...